MedPath

Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

Completed
Conditions
Patients With Alzheimer's Disease
Registration Number
NCT04718207
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

Detailed Description

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

PET technology is improving from year to year thanks to the arrival of a new PET technology called digital. In addition, correction methods have been developed to improve PET images and thus improve the detection of different pathologies in PET.

The PSF (Point Spread Function) tool enables partial volume effects to be corrected. The PSF consists of correcting the impulse response of the system, and allows a visual improvement of the images. Currently not recommended in brain PET/CT reconstructions, it remains to be evaluated for the quantitative analysis of acquisitions.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Brain PET/CT scans at 18F-FDG of patients with Alzheimer's disease carried out in the nuclear medicine department of the Nancy-Brabois University Hospital since December 2017 on digital PET devices.
Exclusion Criteria
  • Patients who have expressed their opposition to the use of their data (poster in the service).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The results obtained in quantitative analysis with and without PSF modelling of PET brain scans of patients with Alzheimer's disease acquired on PET / CT scan6 months

Comparison of the volumes detected by the quantitative analysis with the SPM (statistical parametric Mapping) software of brain PET scans of patients with Alzheimer's disease with and without FSP modelling.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Nuclear medicine department CHRU de NANCY Brabois

🇫🇷

Vandoeuvre les Nancy cedex, France

Nuclear medicine department CHRU de NANCY Brabois
🇫🇷Vandoeuvre les Nancy cedex, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.